Apo-Ketoconazole · DIN 02237235 · 200 mg · tablet
General benefitMarketed · checked November 19, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
1 brand, same coverage
Apo-Ketoconazole · DIN 02237235
Manufacturer: Apotex Inc.; listing date 1999-09-15
Daily cost (source): $0.9393
Health Canada: Marketed since 2021-11-08 · brand APO-KETOCONAZOLE · ATC J02AB02 KETOCONAZOLE · form Tablet · route Oral · ingredients KETOCONAZOLE 200 MG · company Apotex inc · schedule Prescription
Apo-Ketoconazole: Formulary list price $0.94 per unit (the source does not state the unit; exact figure $0.9393). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02237235)
Source record
DIN 02237235: Apo-Ketoconazole
Raw flags: sec3=Y
Item: 081204010; group id 12; item number 0015; lccId None; manufacturer id APX
Source form: Tab; strength: 200mg
Recorded listing: General benefit
Source prices (unrounded): $0.9393; ministry $0.9393
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02237235
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=60554
Therapeutic Notes (formulary)
A low pH is necessary for absorption. Antacids, anticholinergics/antispasmodics, H2-blockers, and omeprazole may decrease absorption. Ketoconazole is a potent inhibitor of hepatic oxidation of drugs and may cause significant elevation of blood levels of astemizole, cisapride, cyclosporine, terfenadine, theophylline and warfarin. Potentially fatal arrhythmias (torsade de pointes) can occur with the combination of ketoconazole and astemizole, cisapride or terfenadine. Insulin requirements may be reduced. Hepatotoxicity occurs in approximately 1 in 1500 patients treated with ketoconazole for onychomycosis; female gender, pre-existing disease, alcoholism and greater than 2 weeks of therapy are pre-disposing factors.
Interchangeable products
Nizoral · DIN 00633836 · not recorded
Teva-Ketoconazole · DIN 02231061 · $0.9393
Shortage status: not checked (no credentials)